A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors

Area of Science:

• Endocrinology
• Oncology
• Neurosurgery

Background:

• Clinically nonfunctioning pituitary tumors (CNFPTs) are often large and invasive at diagnosis.
• Surgical resection is frequently incomplete, and radiotherapy (RT) carries risks like hypopituitarism.
• Current medical therapies for CNFPTs have inconsistent results, highlighting an unmet need for effective treatments.

Purpose of the Study:

• To review the efficacy of medical therapies for clinically nonfunctioning pituitary tumors (CNFPTs).
• To identify current treatment options and assess their outcomes based on published literature.

Main Methods:

• A comprehensive literature search was conducted using the PubMed database.
• Articles published from January 1982 to July 2024 focusing on medical treatment of CNFPTs were reviewed.
• Data on tumor response to somatostatin receptor ligands (SRLs), dopamine D2 receptor agonists, and other agents were analyzed.

Main Results:

• Somatostatin receptor ligands (SRLs) achieved tumor shrinkage in 28% of 111 CNFPT patients.
• Dopamine agonist treatment resulted in tumor shrinkage in 32%, stabilization in 51%, and growth in 17% of 355 patients.
• The efficacy of less common therapies like GnRH analogs, PRRT, and temozolomide was also examined.

Conclusions:

• Existing medical therapies for CNFPTs, including SRLs and dopamine agonists, demonstrate limited efficacy.
• There is a significant need for novel, safe, and effective medical treatments for CNFPTs.
• Robust randomized placebo-controlled clinical trials are essential to advance CNFPT management.